Related Experiment Videos
Myelodysplastic syndrome after cisplatin therapy
R Cheruku1, M Hussain, M Tyrkus
1Department of Internal Medicine, Scott & White Hospital and Clinic, Temple, TX 76508.
Cancer
|July 1, 1993
Summary
Cisplatin, a chemotherapy drug, can cause therapy-related myelodysplastic syndrome (tMDS) and acute nonlymphocytic leukemia (tANLL). This review highlights cisplatin
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Therapy-related myelodysplastic syndrome (tMDS) and acute nonlymphocytic leukemia (tANLL) are recognized late complications of cytotoxic chemotherapy.
- While alkylating agents are common culprits, cisplatin has been increasingly implicated as an etiologic agent.
- Cisplatin's widespread use in treating various cancers, including testicular, ovarian, and head and neck cancers, necessitates understanding its potential long-term adverse effects.
Observation:
- This article details a case of myelodysplastic syndrome developing in a patient after laryngeal cancer treatment with cisplatin, 5-fluorouracil, and radiation.
- A literature review of cisplatin-containing regimens and their association with tMDS/tANLL is presented.
Findings:
- Cisplatin is identified as a potential leukemogenic agent.
- Cisplatin may enhance the leukemogenic effects of other chemotherapy drugs, including alkylating agents and topoisomerase II inhibitors.
Implications:
- The findings underscore the importance of monitoring for tMDS/tANLL in patients treated with cisplatin-based chemotherapy.
- Further research into the mechanisms of cisplatin-induced leukemogenesis is warranted.